Form 4: Kymera Therapeutics' Chief Legal Officer Sells Shares to Cover Tax Obligations

Ellen Chiniara, Chief Legal Officer of Kymera Therapeutics, sold 3,129 shares of common stock on January 6, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On January 6, 2025, Ellen Chiniara, the Chief Legal Officer of Kymera Therapeutics, sold 3,129 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $41.7529, with individual transactions ranging from $41.50 to $41.93.
• Following the transaction, Chiniara beneficially owns 54,826 shares of Kymera Therapeutics stock, which includes shares acquired under the employee stock purchase plan.
• The sale was automatic and not at the discretion of the Reporting Person.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports a transaction by an insider to cover tax obligations, which is a routine event.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This particular transaction appears routine, related to tax obligations from vested equity.

Stakeholder Impact

• The sale of shares by an insider could have a minor, temporary impact on the stock price, but is unlikely to be significant given the reason for the sale.

Key Dates